img

Global Primary Hyperoxaluria Treatment Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Primary Hyperoxaluria Treatment Market Insights, Forecast to 2034

Primary Hyperoxaluria (PH) is a rare genetic disorder caused by deficiencies in glyoxylate metabolism leading to oxalate deposition primarily in kidneys causing end-stage renal disease. It is an inherited autosomal recessive disorder and can be of three types based on the different responsible genestype 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). Signs and symptoms may include recurrent kidney stones, hematuria, and urinary tract infections (UTIs).
Global Primary Hyperoxaluria Treatment market is expected to reach to US$ 666 million in 2024, with a positive growth of %, compared with US$ 633 million in 2022. Backed with the increasing demand from downstream industries, Primary Hyperoxaluria Treatment industry is evaluated to reach US$ 918.3 million in 2029. The CAGR will be 5.5% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Primary Hyperoxaluria Treatment market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Primary Hyperoxaluria Treatment market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Oxthera
Dicerna Pharmaceuticals
Allena Pharmaceuticals
Biocodex
Alnylam Pharmaceuticals
Tecoland Corporation
Zhejiang Tianxin Pharmaceutical
Takeda Pharmaceuticals
Wuxi Further Pharmaceutical
Segment by Type
Oral
Intravenous
Others

Segment by Application


Type 1
Type 2
Type 3

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Primary Hyperoxaluria Treatment plant distribution, commercial date of Primary Hyperoxaluria Treatment, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Primary Hyperoxaluria Treatment introduction, etc. Primary Hyperoxaluria Treatment Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Primary Hyperoxaluria Treatment
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Primary Hyperoxaluria Treatment Product Introduction
1.2 Market by Type
1.2.1 Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Intravenous
1.2.4 Others
1.3 Market by Application
1.3.1 Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Type 1
1.3.3 Type 2
1.3.4 Type 3
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Primary Hyperoxaluria Treatment Sales Estimates and Forecasts 2018-2029
2.2 Global Primary Hyperoxaluria Treatment Revenue by Region
2.2.1 Global Primary Hyperoxaluria Treatment Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Primary Hyperoxaluria Treatment Revenue by Region (2018-2024)
2.2.3 Global Primary Hyperoxaluria Treatment Revenue by Region (2024-2029)
2.2.4 Global Primary Hyperoxaluria Treatment Revenue Market Share by Region (2018-2029)
2.3 Global Primary Hyperoxaluria Treatment Sales Estimates and Forecasts 2018-2029
2.4 Global Primary Hyperoxaluria Treatment Sales by Region
2.4.1 Global Primary Hyperoxaluria Treatment Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Primary Hyperoxaluria Treatment Sales by Region (2018-2024)
2.4.3 Global Primary Hyperoxaluria Treatment Sales by Region (2024-2029)
2.4.4 Global Primary Hyperoxaluria Treatment Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Primary Hyperoxaluria Treatment Sales by Manufacturers
3.1.1 Global Primary Hyperoxaluria Treatment Sales by Manufacturers (2018-2024)
3.1.2 Global Primary Hyperoxaluria Treatment Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Primary Hyperoxaluria Treatment in 2022
3.2 Global Primary Hyperoxaluria Treatment Revenue by Manufacturers
3.2.1 Global Primary Hyperoxaluria Treatment Revenue by Manufacturers (2018-2024)
3.2.2 Global Primary Hyperoxaluria Treatment Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Primary Hyperoxaluria Treatment Revenue in 2022
3.3 Global Key Players of Primary Hyperoxaluria Treatment, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Primary Hyperoxaluria Treatment Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Primary Hyperoxaluria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Primary Hyperoxaluria Treatment, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Primary Hyperoxaluria Treatment, Product Offered and Application
3.8 Global Key Manufacturers of Primary Hyperoxaluria Treatment, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Primary Hyperoxaluria Treatment Sales by Type
4.1.1 Global Primary Hyperoxaluria Treatment Historical Sales by Type (2018-2024)
4.1.2 Global Primary Hyperoxaluria Treatment Forecasted Sales by Type (2024-2029)
4.1.3 Global Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2029)
4.2 Global Primary Hyperoxaluria Treatment Revenue by Type
4.2.1 Global Primary Hyperoxaluria Treatment Historical Revenue by Type (2018-2024)
4.2.2 Global Primary Hyperoxaluria Treatment Forecasted Revenue by Type (2024-2029)
4.2.3 Global Primary Hyperoxaluria Treatment Revenue Market Share by Type (2018-2029)
4.3 Global Primary Hyperoxaluria Treatment Price by Type
4.3.1 Global Primary Hyperoxaluria Treatment Price by Type (2018-2024)
4.3.2 Global Primary Hyperoxaluria Treatment Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Primary Hyperoxaluria Treatment Sales by Application
5.1.1 Global Primary Hyperoxaluria Treatment Historical Sales by Application (2018-2024)
5.1.2 Global Primary Hyperoxaluria Treatment Forecasted Sales by Application (2024-2029)
5.1.3 Global Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2029)
5.2 Global Primary Hyperoxaluria Treatment Revenue by Application
5.2.1 Global Primary Hyperoxaluria Treatment Historical Revenue by Application (2018-2024)
5.2.2 Global Primary Hyperoxaluria Treatment Forecasted Revenue by Application (2024-2029)
5.2.3 Global Primary Hyperoxaluria Treatment Revenue Market Share by Application (2018-2029)
5.3 Global Primary Hyperoxaluria Treatment Price by Application
5.3.1 Global Primary Hyperoxaluria Treatment Price by Application (2018-2024)
5.3.2 Global Primary Hyperoxaluria Treatment Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Primary Hyperoxaluria Treatment Market Size by Type
6.1.1 US & Canada Primary Hyperoxaluria Treatment Sales by Type (2018-2029)
6.1.2 US & Canada Primary Hyperoxaluria Treatment Revenue by Type (2018-2029)
6.2 US & Canada Primary Hyperoxaluria Treatment Market Size by Application
6.2.1 US & Canada Primary Hyperoxaluria Treatment Sales by Application (2018-2029)
6.2.2 US & Canada Primary Hyperoxaluria Treatment Revenue by Application (2018-2029)
6.3 US & Canada Primary Hyperoxaluria Treatment Market Size by Country
6.3.1 US & Canada Primary Hyperoxaluria Treatment Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Primary Hyperoxaluria Treatment Sales by Country (2018-2029)
6.3.3 US & Canada Primary Hyperoxaluria Treatment Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Primary Hyperoxaluria Treatment Market Size by Type
7.1.1 Europe Primary Hyperoxaluria Treatment Sales by Type (2018-2029)
7.1.2 Europe Primary Hyperoxaluria Treatment Revenue by Type (2018-2029)
7.2 Europe Primary Hyperoxaluria Treatment Market Size by Application
7.2.1 Europe Primary Hyperoxaluria Treatment Sales by Application (2018-2029)
7.2.2 Europe Primary Hyperoxaluria Treatment Revenue by Application (2018-2029)
7.3 Europe Primary Hyperoxaluria Treatment Market Size by Country
7.3.1 Europe Primary Hyperoxaluria Treatment Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Primary Hyperoxaluria Treatment Sales by Country (2018-2029)
7.3.3 Europe Primary Hyperoxaluria Treatment Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Primary Hyperoxaluria Treatment Market Size
8.1.1 China Primary Hyperoxaluria Treatment Sales (2018-2029)
8.1.2 China Primary Hyperoxaluria Treatment Revenue (2018-2029)
8.2 China Primary Hyperoxaluria Treatment Market Size by Application
8.2.1 China Primary Hyperoxaluria Treatment Sales by Application (2018-2029)
8.2.2 China Primary Hyperoxaluria Treatment Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Primary Hyperoxaluria Treatment Market Size by Type
9.1.1 Asia Primary Hyperoxaluria Treatment Sales by Type (2018-2029)
9.1.2 Asia Primary Hyperoxaluria Treatment Revenue by Type (2018-2029)
9.2 Asia Primary Hyperoxaluria Treatment Market Size by Application
9.2.1 Asia Primary Hyperoxaluria Treatment Sales by Application (2018-2029)
9.2.2 Asia Primary Hyperoxaluria Treatment Revenue by Application (2018-2029)
9.3 Asia Primary Hyperoxaluria Treatment Sales by Region
9.3.1 Asia Primary Hyperoxaluria Treatment Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Primary Hyperoxaluria Treatment Revenue by Region (2018-2029)
9.3.3 Asia Primary Hyperoxaluria Treatment Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Market Size by Type
10.1.1 Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Market Size by Application
10.2.1 Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales by Country
10.3.1 Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Oxthera
11.1.1 Oxthera Company Information
11.1.2 Oxthera Overview
11.1.3 Oxthera Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Oxthera Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Oxthera Recent Developments
11.2 Dicerna Pharmaceuticals
11.2.1 Dicerna Pharmaceuticals Company Information
11.2.2 Dicerna Pharmaceuticals Overview
11.2.3 Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Dicerna Pharmaceuticals Recent Developments
11.3 Allena Pharmaceuticals
11.3.1 Allena Pharmaceuticals Company Information
11.3.2 Allena Pharmaceuticals Overview
11.3.3 Allena Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Allena Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Allena Pharmaceuticals Recent Developments
11.4 Biocodex
11.4.1 Biocodex Company Information
11.4.2 Biocodex Overview
11.4.3 Biocodex Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Biocodex Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Biocodex Recent Developments
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Information
11.5.2 Alnylam Pharmaceuticals Overview
11.5.3 Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Alnylam Pharmaceuticals Recent Developments
11.6 Tecoland Corporation
11.6.1 Tecoland Corporation Company Information
11.6.2 Tecoland Corporation Overview
11.6.3 Tecoland Corporation Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Tecoland Corporation Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Tecoland Corporation Recent Developments
11.7 Zhejiang Tianxin Pharmaceutical
11.7.1 Zhejiang Tianxin Pharmaceutical Company Information
11.7.2 Zhejiang Tianxin Pharmaceutical Overview
11.7.3 Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Zhejiang Tianxin Pharmaceutical Recent Developments
11.8 Takeda Pharmaceuticals
11.8.1 Takeda Pharmaceuticals Company Information
11.8.2 Takeda Pharmaceuticals Overview
11.8.3 Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Takeda Pharmaceuticals Recent Developments
11.9 Wuxi Further Pharmaceutical
11.9.1 Wuxi Further Pharmaceutical Company Information
11.9.2 Wuxi Further Pharmaceutical Overview
11.9.3 Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Wuxi Further Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Primary Hyperoxaluria Treatment Industry Chain Analysis
12.2 Primary Hyperoxaluria Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Primary Hyperoxaluria Treatment Production Mode & Process
12.4 Primary Hyperoxaluria Treatment Sales and Marketing
12.4.1 Primary Hyperoxaluria Treatment Sales Channels
12.4.2 Primary Hyperoxaluria Treatment Distributors
12.5 Primary Hyperoxaluria Treatment Customers
13 Market Dynamics
13.1 Primary Hyperoxaluria Treatment Industry Trends
13.2 Primary Hyperoxaluria Treatment Market Drivers
13.3 Primary Hyperoxaluria Treatment Market Challenges
13.4 Primary Hyperoxaluria Treatment Market Restraints
14 Key Findings in The Global Primary Hyperoxaluria Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Oral
Table 3. Major Manufacturers of Intravenous
Table 4. Major Manufacturers of Others
Table 5. Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Primary Hyperoxaluria Treatment Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Primary Hyperoxaluria Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Primary Hyperoxaluria Treatment Revenue by Region (2024-2029) & (US$ Million)
Table 9. Global Primary Hyperoxaluria Treatment Revenue Market Share by Region (2018-2024)
Table 10. Global Primary Hyperoxaluria Treatment Revenue Market Share by Region (2024-2029)
Table 11. Global Primary Hyperoxaluria Treatment Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Primary Hyperoxaluria Treatment Sales by Region (2018-2024) & (K Units)
Table 13. Global Primary Hyperoxaluria Treatment Sales by Region (2024-2029) & (K Units)
Table 14. Global Primary Hyperoxaluria Treatment Sales Market Share by Region (2018-2024)
Table 15. Global Primary Hyperoxaluria Treatment Sales Market Share by Region (2024-2029)
Table 16. Global Primary Hyperoxaluria Treatment Sales by Manufacturers (2018-2024) & (K Units)
Table 17. Global Primary Hyperoxaluria Treatment Sales Share by Manufacturers (2018-2024)
Table 18. Global Primary Hyperoxaluria Treatment Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Primary Hyperoxaluria Treatment Revenue Share by Manufacturers (2018-2024)
Table 20. Global Key Players of Primary Hyperoxaluria Treatment, Industry Ranking, 2021 VS 2022 VS 2024
Table 21. Primary Hyperoxaluria Treatment Price by Manufacturers 2018-2024 (US$/Unit)
Table 22. Global Primary Hyperoxaluria Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Primary Hyperoxaluria Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Hyperoxaluria Treatment as of 2022)
Table 24. Global Key Manufacturers of Primary Hyperoxaluria Treatment, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Primary Hyperoxaluria Treatment, Product Offered and Application
Table 26. Global Key Manufacturers of Primary Hyperoxaluria Treatment, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Primary Hyperoxaluria Treatment Sales by Type (2018-2024) & (K Units)
Table 29. Global Primary Hyperoxaluria Treatment Sales by Type (2024-2029) & (K Units)
Table 30. Global Primary Hyperoxaluria Treatment Sales Share by Type (2018-2024)
Table 31. Global Primary Hyperoxaluria Treatment Sales Share by Type (2024-2029)
Table 32. Global Primary Hyperoxaluria Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Primary Hyperoxaluria Treatment Revenue by Type (2024-2029) & (US$ Million)
Table 34. Global Primary Hyperoxaluria Treatment Revenue Share by Type (2018-2024)
Table 35. Global Primary Hyperoxaluria Treatment Revenue Share by Type (2024-2029)
Table 36. Primary Hyperoxaluria Treatment Price by Type (2018-2024) & (US$/Unit)
Table 37. Global Primary Hyperoxaluria Treatment Price Forecast by Type (2024-2029) & (US$/Unit)
Table 38. Global Primary Hyperoxaluria Treatment Sales by Application (2018-2024) & (K Units)
Table 39. Global Primary Hyperoxaluria Treatment Sales by Application (2024-2029) & (K Units)
Table 40. Global Primary Hyperoxaluria Treatment Sales Share by Application (2018-2024)
Table 41. Global Primary Hyperoxaluria Treatment Sales Share by Application (2024-2029)
Table 42. Global Primary Hyperoxaluria Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Primary Hyperoxaluria Treatment Revenue by Application (2024-2029) & (US$ Million)
Table 44. Global Primary Hyperoxaluria Treatment Revenue Share by Application (2018-2024)
Table 45. Global Primary Hyperoxaluria Treatment Revenue Share by Application (2024-2029)
Table 46. Primary Hyperoxaluria Treatment Price by Application (2018-2024) & (US$/Unit)
Table 47. Global Primary Hyperoxaluria Treatment Price Forecast by Application (2024-2029) & (US$/Unit)
Table 48. US & Canada Primary Hyperoxaluria Treatment Sales by Type (2018-2024) & (K Units)
Table 49. US & Canada Primary Hyperoxaluria Treatment Sales by Type (2024-2029) & (K Units)
Table 50. US & Canada Primary Hyperoxaluria Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 51. US & Canada Primary Hyperoxaluria Treatment Revenue by Type (2024-2029) & (US$ Million)
Table 52. US & Canada Primary Hyperoxaluria Treatment Sales by Application (2018-2024) & (K Units)
Table 53. US & Canada Primary Hyperoxaluria Treatment Sales by Application (2024-2029) & (K Units)
Table 54. US & Canada Primary Hyperoxaluria Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 55. US & Canada Primary Hyperoxaluria Treatment Revenue by Application (2024-2029) & (US$ Million)
Table 56. US & Canada Primary Hyperoxaluria Treatment Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 57. US & Canada Primary Hyperoxaluria Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 58. US & Canada Primary Hyperoxaluria Treatment Revenue by Country (2024-2029) & (US$ Million)
Table 59. US & Canada Primary Hyperoxaluria Treatment Sales by Country (2018-2024) & (K Units)
Table 60. US & Canada Primary Hyperoxaluria Treatment Sales by Country (2024-2029) & (K Units)
Table 61. Europe Primary Hyperoxaluria Treatment Sales by Type (2018-2024) & (K Units)
Table 62. Europe Primary Hyperoxaluria Treatment Sales by Type (2024-2029) & (K Units)
Table 63. Europe Primary Hyperoxaluria Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 64. Europe Primary Hyperoxaluria Treatment Revenue by Type (2024-2029) & (US$ Million)
Table 65. Europe Primary Hyperoxaluria Treatment Sales by Application (2018-2024) & (K Units)
Table 66. Europe Primary Hyperoxaluria Treatment Sales by Application (2024-2029) & (K Units)
Table 67. Europe Primary Hyperoxaluria Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 68. Europe Primary Hyperoxaluria Treatment Revenue by Application (2024-2029) & (US$ Million)
Table 69. Europe Primary Hyperoxaluria Treatment Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 70. Europe Primary Hyperoxaluria Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 71. Europe Primary Hyperoxaluria Treatment Revenue by Country (2024-2029) & (US$ Million)
Table 72. Europe Primary Hyperoxaluria Treatment Sales by Country (2018-2024) & (K Units)
Table 73. Europe Primary Hyperoxaluria Treatment Sales by Country (2024-2029) & (K Units)
Table 74. China Primary Hyperoxaluria Treatment Sales by Type (2018-2024) & (K Units)
Table 75. China Primary Hyperoxaluria Treatment Sales by Type (2024-2029) & (K Units)
Table 76. China Primary Hyperoxaluria Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 77. China Primary Hyperoxaluria Treatment Revenue by Type (2024-2029) & (US$ Million)
Table 78. China Primary Hyperoxaluria Treatment Sales by Application (2018-2024) & (K Units)
Table 79. China Primary Hyperoxaluria Treatment Sales by Application (2024-2029) & (K Units)
Table 80. China Primary Hyperoxaluria Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 81. China Primary Hyperoxaluria Treatment Revenue by Application (2024-2029) & (US$ Million)
Table 82. Asia Primary Hyperoxaluria Treatment Sales by Type (2018-2024) & (K Units)
Table 83. Asia Primary Hyperoxaluria Treatment Sales by Type (2024-2029) & (K Units)
Table 84. Asia Primary Hyperoxaluria Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 85. Asia Primary Hyperoxaluria Treatment Revenue by Type (2024-2029) & (US$ Million)
Table 86. Asia Primary Hyperoxaluria Treatment Sales by Application (2018-2024) & (K Units)
Table 87. Asia Primary Hyperoxaluria Treatment Sales by Application (2024-2029) & (K Units)
Table 88. Asia Primary Hyperoxaluria Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 89. Asia Primary Hyperoxaluria Treatment Revenue by Application (2024-2029) & (US$ Million)
Table 90. Asia Primary Hyperoxaluria Treatment Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 91. Asia Primary Hyperoxaluria Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 92. Asia Primary Hyperoxaluria Treatment Revenue by Region (2024-2029) & (US$ Million)
Table 93. Asia Primary Hyperoxaluria Treatment Sales by Region (2018-2024) & (K Units)
Table 94. Asia Primary Hyperoxaluria Treatment Sales by Region (2024-2029) & (K Units)
Table 95. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales by Type (2018-2024) & (K Units)
Table 96. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales by Type (2024-2029) & (K Units)
Table 97. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue by Type (2024-2029) & (US$ Million)
Table 99. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales by Application (2018-2024) & (K Units)
Table 100. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales by Application (2024-2029) & (K Units)
Table 101. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue by Application (2024-2029) & (US$ Million)
Table 103. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 104. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue by Country (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales by Country (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales by Country (2024-2029) & (K Units)
Table 108. Oxthera Company Information
Table 109. Oxthera Description and Major Businesses
Table 110. Oxthera Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. Oxthera Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Oxthera Recent Developments
Table 113. Dicerna Pharmaceuticals Company Information
Table 114. Dicerna Pharmaceuticals Description and Major Businesses
Table 115. Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Dicerna Pharmaceuticals Recent Developments
Table 118. Allena Pharmaceuticals Company Information
Table 119. Allena Pharmaceuticals Description and Major Businesses
Table 120. Allena Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Allena Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Allena Pharmaceuticals Recent Developments
Table 123. Biocodex Company Information
Table 124. Biocodex Description and Major Businesses
Table 125. Biocodex Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. Biocodex Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Biocodex Recent Developments
Table 128. Alnylam Pharmaceuticals Company Information
Table 129. Alnylam Pharmaceuticals Description and Major Businesses
Table 130. Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Alnylam Pharmaceuticals Recent Developments
Table 133. Tecoland Corporation Company Information
Table 134. Tecoland Corporation Description and Major Businesses
Table 135. Tecoland Corporation Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. Tecoland Corporation Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Tecoland Corporation Recent Developments
Table 138. Zhejiang Tianxin Pharmaceutical Company Information
Table 139. Zhejiang Tianxin Pharmaceutical Description and Major Businesses
Table 140. Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 141. Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Zhejiang Tianxin Pharmaceutical Recent Developments
Table 143. Takeda Pharmaceuticals Company Information
Table 144. Takeda Pharmaceuticals Description and Major Businesses
Table 145. Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 146. Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Takeda Pharmaceuticals Recent Developments
Table 148. Wuxi Further Pharmaceutical Company Information
Table 149. Wuxi Further Pharmaceutical Description and Major Businesses
Table 150. Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 151. Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. Wuxi Further Pharmaceutical Recent Developments
Table 153. Key Raw Materials Lists
Table 154. Raw Materials Key Suppliers Lists
Table 155. Primary Hyperoxaluria Treatment Distributors List
Table 156. Primary Hyperoxaluria Treatment Customers List
Table 157. Primary Hyperoxaluria Treatment Market Trends
Table 158. Primary Hyperoxaluria Treatment Market Drivers
Table 159. Primary Hyperoxaluria Treatment Market Challenges
Table 160. Primary Hyperoxaluria Treatment Market Restraints
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Primary Hyperoxaluria Treatment Product Picture
Figure 2. Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Primary Hyperoxaluria Treatment Market Share by Type in 2022 & 2029
Figure 4. Oral Product Picture
Figure 5. Intravenous Product Picture
Figure 6. Others Product Picture
Figure 7. Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Primary Hyperoxaluria Treatment Market Share by Application in 2022 & 2029
Figure 9. Type 1
Figure 10. Type 2
Figure 11. Type 3
Figure 12. Primary Hyperoxaluria Treatment Report Years Considered
Figure 13. Global Primary Hyperoxaluria Treatment Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Primary Hyperoxaluria Treatment Revenue 2018-2029 (US$ Million)
Figure 15. Global Primary Hyperoxaluria Treatment Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 16. Global Primary Hyperoxaluria Treatment Revenue Market Share by Region (2018-2029)
Figure 17. Global Primary Hyperoxaluria Treatment Sales 2018-2029 ((K Units)
Figure 18. Global Primary Hyperoxaluria Treatment Sales Market Share by Region (2018-2029)
Figure 19. US & Canada Primary Hyperoxaluria Treatment Sales YoY (2018-2029) & (K Units)
Figure 20. US & Canada Primary Hyperoxaluria Treatment Revenue YoY (2018-2029) & (US$ Million)
Figure 21. Europe Primary Hyperoxaluria Treatment Sales YoY (2018-2029) & (K Units)
Figure 22. Europe Primary Hyperoxaluria Treatment Revenue YoY (2018-2029) & (US$ Million)
Figure 23. China Primary Hyperoxaluria Treatment Sales YoY (2018-2029) & (K Units)
Figure 24. China Primary Hyperoxaluria Treatment Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Asia (excluding China) Primary Hyperoxaluria Treatment Sales YoY (2018-2029) & (K Units)
Figure 26. Asia (excluding China) Primary Hyperoxaluria Treatment Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales YoY (2018-2029) & (K Units)
Figure 28. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue YoY (2018-2029) & (US$ Million)
Figure 29. The Primary Hyperoxaluria Treatment Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Primary Hyperoxaluria Treatment in the World: Market Share by Primary Hyperoxaluria Treatment Revenue in 2022
Figure 31. Global Primary Hyperoxaluria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2029)
Figure 33. Global Primary Hyperoxaluria Treatment Revenue Market Share by Type (2018-2029)
Figure 34. Global Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2029)
Figure 35. Global Primary Hyperoxaluria Treatment Revenue Market Share by Application (2018-2029)
Figure 36. US & Canada Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2029)
Figure 37. US & Canada Primary Hyperoxaluria Treatment Revenue Market Share by Type (2018-2029)
Figure 38. US & Canada Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2029)
Figure 39. US & Canada Primary Hyperoxaluria Treatment Revenue Market Share by Application (2018-2029)
Figure 40. US & Canada Primary Hyperoxaluria Treatment Revenue Share by Country (2018-2029)
Figure 41. US & Canada Primary Hyperoxaluria Treatment Sales Share by Country (2018-2029)
Figure 42. U.S. Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 43. Canada Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 44. Europe Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2029)
Figure 45. Europe Primary Hyperoxaluria Treatment Revenue Market Share by Type (2018-2029)
Figure 46. Europe Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2029)
Figure 47. Europe Primary Hyperoxaluria Treatment Revenue Market Share by Application (2018-2029)
Figure 48. Europe Primary Hyperoxaluria Treatment Revenue Share by Country (2018-2029)
Figure 49. Europe Primary Hyperoxaluria Treatment Sales Share by Country (2018-2029)
Figure 50. Germany Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 51. France Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 52. U.K. Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 53. Italy Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 54. Russia Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 55. China Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2029)
Figure 56. China Primary Hyperoxaluria Treatment Revenue Market Share by Type (2018-2029)
Figure 57. China Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2029)
Figure 58. China Primary Hyperoxaluria Treatment Revenue Market Share by Application (2018-2029)
Figure 59. Asia Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2029)
Figure 60. Asia Primary Hyperoxaluria Treatment Revenue Market Share by Type (2018-2029)
Figure 61. Asia Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2029)
Figure 62. Asia Primary Hyperoxaluria Treatment Revenue Market Share by Application (2018-2029)
Figure 63. Asia Primary Hyperoxaluria Treatment Revenue Share by Region (2018-2029)
Figure 64. Asia Primary Hyperoxaluria Treatment Sales Share by Region (2018-2029)
Figure 65. Japan Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 66. South Korea Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 67. China Taiwan Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 68. Southeast Asia Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 69. India Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Revenue Share by Country (2018-2029)
Figure 75. Middle East, Africa and Latin America Primary Hyperoxaluria Treatment Sales Share by Country (2018-2029)
Figure 76. Brazil Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 77. Mexico Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 78. Turkey Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 79. Israel Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 80. GCC Countries Primary Hyperoxaluria Treatment Revenue (2018-2029) & (US$ Million)
Figure 81. Primary Hyperoxaluria Treatment Value Chain
Figure 82. Primary Hyperoxaluria Treatment Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries